Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

121 questions · 129 findings · 16 reviews

No studies found 32 · 24.8%GRADE not reported 17 · 13.2%Very low 29 · 22.5%Low 17 · 13.2%Moderate 30 · 23.3%High 4 · 3.1%

Azithromycin (500 mg 20 ‐ 28 days) vs meglumine antimoniate (15 ‐ 20 mg/kg/d

Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis

Azithromycin (500 mg 20 ‐ 28 days) probably leads to lower complete cure, at least 3 months after the end of treatment compared with meglumine antimoniate (15 ‐ 20 mg/kg/d (moderate certainty).

1 finding from 1 review

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Clinical cure according to criteria established by study authors Mild‐moderate PID · women with PID

It is very uncertain whether regimens containing macrolides (azithromycin) changes clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (very low certainty).

2 findings from 1 review

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Clinical cure according to criteria established by study authors Severe PID · women with PID

Regimens containing macrolides (azithromycin) showed no clear difference in clinical cure according to criteria established by study authors… compared with regimens containing tetracycline (doxycycline) (low certainty).

1 finding from 1 review

Regimens containing macrolides (azithromycin) vs regimens containing tetracycline (doxycycline)

Adverse events: any antibiotic‐related adverse event leading to discontinuation of therapy · women with PID

Regimens containing macrolides (azithromycin) showed no clear difference in adverse events: any antibiotic‐related adverse event leading to… compared with regimens containing tetracycline (doxycycline) (low certainty).

1 finding from 1 review

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Eradication of P aeruginosa from the respiratory tract: number of participants eradicated after three month treatment phase · children with cystic fibrosis and a new culture positive for P aeruginosa

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in eradication of P aeruginosa from the respiratory tract: number of… compared with TNS plus oral placebo (low certainty).

1 finding from 1 review

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Frequency of infective pulmonary exacerbations: number of participants experiencing an exacerbation · children with cystic fibrosis and a new culture positive for P aeruginosa

Inhaled tobramycin (TNS) plus oral azithromycin showed no clear difference in frequency of infective pulmonary exacerbations: number of… compared with TNS plus oral placebo (moderate certainty).

1 finding from 1 review

Inhaled tobramycin (TNS) plus oral azithromycin vs TNS plus oral placebo

Isolation of other micro‐organisms from the respiratory tract: number of participants isolating other micro‐organisms within the 15‐month · children with cystic fibrosis and a new culture positive for P aeruginosa
1 finding from 1 review